Original Research
Accepted on 29 Sep 2025
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China
in Health Economics
- 164 views
Original Research
Accepted on 29 Sep 2025
in Health Economics
Original Research
Accepted on 29 Sep 2025
in Psychology for Clinical Settings
Systematic Review
Accepted on 29 Sep 2025
in Pediatric Surgery
Opinion
Accepted on 29 Sep 2025
in Implementation Science
Original Research
Accepted on 29 Sep 2025
in Family Medicine and Primary Care
Original Research
Accepted on 29 Sep 2025
in Visceral Surgery
Review
Accepted on 29 Sep 2025
in Antimicrobials, Resistance and Chemotherapy
Original Research
Accepted on 29 Sep 2025
in Gynecological Oncology
Original Research
Accepted on 29 Sep 2025
in Georeservoirs
Case Report
Accepted on 29 Sep 2025
in Genetics of Common and Rare Diseases
Original Research
Accepted on 29 Sep 2025
in Synthetic Biology
Original Research
Accepted on 29 Sep 2025
in Visceral Surgery
Original Research
Accepted on 29 Sep 2025
in Higher Education
Original Research
Accepted on 29 Sep 2025
in Aging and Public Health
Original Research
Accepted on 29 Sep 2025
in Coastal Ocean Processes
Original Research
Accepted on 29 Sep 2025
in Public Health Education and Promotion